Academic Journal
277P Nivolumab (NIVO) plus gemcitabine-cisplatin (GC) vs GC alone for previously untreated unresectable or metastatic urothelial carcinoma (u/mUC): Chinese population analysis results from the phase III CheckMate 901 trial
| العنوان: | 277P Nivolumab (NIVO) plus gemcitabine-cisplatin (GC) vs GC alone for previously untreated unresectable or metastatic urothelial carcinoma (u/mUC): Chinese population analysis results from the phase III CheckMate 901 trial |
|---|---|
| المؤلفون: | Ye, D., He, Z., Zou, Q., Wang, Z., Xu, D., Zhang, P., Dong, H., Liu, Z., Guo, J., Cao, X., Yuan, X., Chen, J., Hu, Y., Tsai, Y-C., Kang, W., Filian, J., Wang, L., Luo, H. |
| المساهمون: | Bristol-Myers Squibb |
| المصدر: | Annals of Oncology ; volume 35, page S1511 ; ISSN 0923-7534 |
| بيانات النشر: | Elsevier BV |
| سنة النشر: | 2024 |
| المجموعة: | ScienceDirect (Elsevier - Open Access Articles via Crossref) |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1016/j.annonc.2024.10.297 |
| الاتاحة: | https://doi.org/10.1016/j.annonc.2024.10.297 https://api.elsevier.com/content/article/PII:S0923753424043539?httpAccept=text/xml https://api.elsevier.com/content/article/PII:S0923753424043539?httpAccept=text/plain |
| Rights: | https://www.elsevier.com/tdm/userlicense/1.0/ ; https://www.elsevier.com/legal/tdmrep-license |
| رقم الانضمام: | edsbas.BE874228 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.annonc.2024.10.297 |
|---|